<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H559C3A7DB3B34FE2A0716CC54CA91BD1" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 1405 IH: Enhancing Domestic Drug Manufacturing Competitiveness Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-02-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1405</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250218">February 18, 2025</action-date><action-desc><sponsor name-id="B001260">Mr. Buchanan</sponsor> (for himself and <cosponsor name-id="D000032">Mr. Donalds</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.</official-title></form><legis-body id="H0AB32CDA28084F61BF5B0F85D88BFF19" style="OLC"><section id="H51ECD1D3BF7F4C71814ADCA029166AE6" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Enhancing Domestic Drug Manufacturing Competitiveness Act</short-title></quote>. </text></section><section id="H66E92F9049D041578CD3FECED10A32A4"><enum>2.</enum><header>Study on key regulatory barriers to expanding pharmaceutical manufacturing in the United States</header><subsection id="H7EBDC7C4BB5B4970B7E99002907344F5"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Comptroller General of the United States shall conduct a study to identify, and to assess on a time and cost basis, the key regulatory barriers that—</text><paragraph id="H436DAF8699CB46F3BAC1C6943B4719F8"><enum>(1)</enum><text>impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States; or</text></paragraph><paragraph id="H4D95761E5DCE46B086C984CCA37C9A04"><enum>(2)</enum><text>make the United States less competitive than other countries as a location for such facilities.</text></paragraph></subsection><subsection id="H97D69179049D439080F985DDE3DAB74D"><enum>(b)</enum><header>Questions</header><text>In conducting the study under subsection (a), the Comptroller General shall consider the following questions:</text><paragraph id="H28EA6C653538401A9D1D0B0A2518FC5C"><enum>(1)</enum><text>Do environmental or other regulations significantly delay, and increase the costs for manufacturers of, expanding or siting pharmaceutical manufacturing facilities in the United States relative to environmental or other regulations in other countries?</text></paragraph><paragraph id="H9E5DA2EB9FD7480893C8D7C028836A8A"><enum>(2)</enum><text>What is the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency?</text></paragraph><paragraph id="HCCB1F60B6AD34D539175CD0F2808903C"><enum>(3)</enum><text>What specific actions (such as expediting reviews, inspections, and approvals of new facilities or changes to existing facilities) could be taken by regulators to address the regulatory barriers described in subsection (a)?</text></paragraph></subsection><subsection id="HF16FC9B8A002470BB87F1C12B09C093C"><enum>(c)</enum><header>Engaging stakeholders</header><text>In conducting the study under subsection (a), the Comptroller General shall engage stakeholders—</text><paragraph id="H1F626B8563044DD29FBCEFDE08F81A84"><enum>(1)</enum><text>to identify and assess the barriers described in subsection (a);</text></paragraph><paragraph id="H8A5B461906FF4FBF8C9DFF54B64B9024"><enum>(2)</enum><text>to identify whether there are promising technological solutions, including manufacturing processes, that could help to address the regulatory barriers described in subsection (a); and</text></paragraph><paragraph id="HCAA05C93263C4A028242FCA6A22F1AA8"><enum>(3)</enum><text>to identify the policies needed to support and foster any solutions identified pursuant to paragraph (2).</text></paragraph></subsection><subsection id="H86F83C457315455AB789134806F97951"><enum>(d)</enum><header>Report</header><paragraph id="HA8DF7D0380BC4D05A787465C959C5133"><enum>(1)</enum><header>In general</header><text>Not later than 1 year after the date of enactment of this Act, the Comptroller General shall complete the study under subsection (a) and submit to the Congress a report on the results of such study.</text></paragraph><paragraph id="H3A65BF6760CC472F86269B527122305B"><enum>(2)</enum><header>Contents</header><text>The report required by paragraph (1) shall—</text><subparagraph id="H387305887EA74323A2788ADB72A0EED2"><enum>(A)</enum><text display-inline="yes-display-inline">identify, and assess on a time and cost basis, the regulatory barriers described in subsection (a);</text></subparagraph><subparagraph id="H71BDF36332DC4232A5997C568029FAF0"><enum>(B)</enum><text>address each question listed in subsection (b); and</text></subparagraph><subparagraph id="H553E21B0BCA64A6FB164740FCA4E0137"><enum>(C)</enum><text>include recommendations for streamlining the regulatory barriers described in subsection (a), and facilitating the use of technological solutions described in subsection (c)(2), to foster increased pharmaceutical manufacturing in the United States.</text></subparagraph></paragraph></subsection></section></legis-body></bill> 

